[Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)]
- PMID: 137852
- DOI: 10.1055/s-0029-1230516
[Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)]
Abstract
Following high dose radio-iodine therapy, some radiation damage to the salivary glands is to be expected since iodine is taken up by these glands. The great individual variation in the uptake makes it impossible to predict the severity of the damage. T max and maximal excretion capacity after stimulation were therefore estimated by a camera functional scintigram with digital read out in patients following radioiodine therapy (0.1-3.2 Ci); the excretion index was used as an indirect measure of salivary flow. After a dose up to 0.3 Ci there is a change of T max and maximal excretion capacity in 30% of patients; after a dose of 0.5 to 1 Ci it is found in 60 and 80% and after very high doses of 1.1 to 3.2 Ci an abnormal Tmax was found in two-thirds of all patients and reduced or absent excretion capacity in all nine patients in this group. The excretion index also depended significantly on the cumulative dose. All patients who had received very high doses showed marked hyposialia or asialia. The early results of interim examinations suggest, similar to radio-iodine induced hypothyroidism, a cumulative risk of reduced function. In view of the long survival period of patients with differentiated thyroid carcinomas attention should be drawn to this side effect.
Similar articles
-
Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?J Nucl Med. 2005 Feb;46(2):261-6. J Nucl Med. 2005. PMID: 15695785 Clinical Trial.
-
[Clinical picture and possible causes of functional disorders of the parotid gland in radioiodine therapy of differentiated thyroid cancer].Laryngol Rhinol Otol (Stuttg). 1988 Jul;67(7):362-6. Laryngol Rhinol Otol (Stuttg). 1988. PMID: 3210869 German.
-
Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.Med Phys. 2011 Oct;38(10):5412-9. doi: 10.1118/1.3602459. Med Phys. 2011. PMID: 21992360
-
Radioactive iodine and the salivary glands.Thyroid. 2003 Mar;13(3):265-71. doi: 10.1089/105072503321582060. Thyroid. 2003. PMID: 12729475 Review.
-
Sialoadenitis secondary to ¹³¹I therapy for well-differentiated thyroid cancer.Oral Dis. 2011 Mar;17(2):154-61. doi: 10.1111/j.1601-0825.2010.01726.x. Epub 2010 Oct 28. Oral Dis. 2011. PMID: 21029259 Review.
Cited by
-
Early immunohistochemical and functional markers indicating radiation damage of the parotid gland.Clin Oral Investig. 2004 Mar;8(1):30-5. doi: 10.1007/s00784-003-0249-9. Epub 2004 Jan 21. Clin Oral Investig. 2004. PMID: 14735331
-
Strategies for Radioiodine Treatment: What's New.Cancers (Basel). 2022 Aug 4;14(15):3800. doi: 10.3390/cancers14153800. Cancers (Basel). 2022. PMID: 35954463 Free PMC article. Review.
-
Evaluation and management of dry mouth and its complications in rheumatology practice.Expert Rev Clin Immunol. 2024 Jan-Jun;20(1):1-19. doi: 10.1080/1744666X.2023.2268283. Epub 2024 Jan 8. Expert Rev Clin Immunol. 2024. PMID: 37823475 Free PMC article. Review.
-
Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1778-85. doi: 10.1007/s00259-009-1368-6. Epub 2010 Feb 4. Eur J Nucl Med Mol Imaging. 2010. PMID: 20130857 Review.
-
Amifostine for salivary glands in high-dose radioactive iodine treated differentiated thyroid cancer.Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD007956. doi: 10.1002/14651858.CD007956.pub2. Cochrane Database Syst Rev. 2009. PMID: 19821441 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources